Characteristics of previously untreated patients treated with hyperCVAD plus TKI and achieving CR after 1 course
| Characteristics . | HyperCVAD + dasatinib . | HyperCVAD + imatinib . | Overall . |
|---|---|---|---|
| N | 48 | 28 | 76 |
| Median age, y (range) | 55 (21-78) | 53 (28-84) | 54 (21-84) |
| Median WBC, ×109/L (range) | 11.4 (0.4-658.1) | 10.4 (3.7-211) | 10.8 (0.4-658.1) |
| Performance status, n (%) | |||
| 0-1 | 46 (96) | 24 (86) | 70 (92) |
| 2 | 2 (4) | 4 (14) | 6 (8) |
| CNS disease at Dx | 3 (6) | 0 | 3 (4) |
| Cytogenetics, n (%) | |||
| Ph+ | 9 (19) | 4 (14) | 13 (17) |
| Ph+ plus other | 34 (71) | 16 (57) | 50 (66) |
| IM/ND (BCR-ABL+) | 5 (10) | 8 (29) | 13 (17) |
| Molecular, n (%) | |||
| e1a2 or e1a3 | 38 (79) | 20 (71) | 58 (76) |
| e13a2 or e14a2 | 10 (21) | 8 (29) | 18 (24) |
| CD20 expression, ≥20% | 27 (56) | 19 (68) | 46 (61) |
| Characteristics . | HyperCVAD + dasatinib . | HyperCVAD + imatinib . | Overall . |
|---|---|---|---|
| N | 48 | 28 | 76 |
| Median age, y (range) | 55 (21-78) | 53 (28-84) | 54 (21-84) |
| Median WBC, ×109/L (range) | 11.4 (0.4-658.1) | 10.4 (3.7-211) | 10.8 (0.4-658.1) |
| Performance status, n (%) | |||
| 0-1 | 46 (96) | 24 (86) | 70 (92) |
| 2 | 2 (4) | 4 (14) | 6 (8) |
| CNS disease at Dx | 3 (6) | 0 | 3 (4) |
| Cytogenetics, n (%) | |||
| Ph+ | 9 (19) | 4 (14) | 13 (17) |
| Ph+ plus other | 34 (71) | 16 (57) | 50 (66) |
| IM/ND (BCR-ABL+) | 5 (10) | 8 (29) | 13 (17) |
| Molecular, n (%) | |||
| e1a2 or e1a3 | 38 (79) | 20 (71) | 58 (76) |
| e13a2 or e14a2 | 10 (21) | 8 (29) | 18 (24) |
| CD20 expression, ≥20% | 27 (56) | 19 (68) | 46 (61) |
Dx, diagnosis; IM/ND, insufficient metaphases/not done.